Introduction
Colorectal cancer (CRC) is the third most frequent cause of cancer death worldwide. 1 CRC develops progressively through accumulation of genetic lesions in the epithelial cell layer. While these modifications can contribute to tumor progression through increased proliferation and decreased apoptosis, the molecular mechanisms that are responsible for metastasis remain to be unraveled. 2 The liver is the most common site of hematogenous metastasis in CRC. At the time of the diagnosis, approximately 20% of patients present with synchronous liver metastasis and another 20-30% of patients will develop liver metastasis after resection of the primary colorectal tumor. 3 The 5-year survival rate for CRC patients is approximately 80-90%, while for those showing distant metastasis it is only 10-20%. 4 Complete surgical resection of liver metastases remains the only potentially curative treatment for patients with liver metastases and results in a 1-year survival rate of approximately 36%. 5 However, relapse after resection occurs in 75% of patients. 6 The pathogenic pathways involved in mCRC include the epidermal growth factor receptor (EGFR) cascade and vascular endothelial growth factor (VEGF) signaling. 7 Randomized phase III clinical trials have shown that targeting EGFR with monoclonal antibodies, such as cetuximab and panitumumab results in improved outcomes in mCRC patients with wildtype Ras oncogene. 8 Furthermore, given the crucial importance of neoangiogenesis in mCRC, therapies targeting the VEGF pathway have been intensively investigated. 9 VEGF-A was shown to be the predominant pro-angiogenic factor in CRC and its presence was associated with metastases formation and poor prognosis. 10 Ellis and colleagues have demonstrated that anti-angiogenic therapy targeting the tyrosine kinase VEGF receptor inhibits the vascularity, proliferation and growth of colon cancer liver metastases and significantly increases endothelial and tumor cell apoptosis, suggesting an important role for VEGF as a survival factor for tumor endothelium. 10 The monoclonal antibody bevacizumab is the first anti-angiogenic agent to be approved for the treatment of mCRC, based on both response rate and survival benefit.
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Three anti-angiogenic drugs have been recently included into the treatment of mCRC: aflibercept and ramucirumab are biological compounds directed against the extracellular domains of human VEGF receptors, while the chemical compound regorafenib is an orally active VEGFR2-TIE2 tyrosine kinase inhibitor. Nevertheless, survival benefits remain modest and the 5-year survival rate is approximately 10%. 12 Furthermore, in contrast to therapies targeting EGFR, there is no therapeutic biomarker enabling clinicians to select the patient population who would benefit from this class of therapy. Figure 1 illustrates the current anti-angiogenic drugs approved for mCRC treatment and their mechanisms of action.
Based on an overview of anti-angiogenic treatment regimens for CRC and mCRC, in this review we summarize the current knowledge of genetic variations in the VEGF pathways with relation to their prognostic and therapeutic value in mCRC patients. We also discuss the potential use of VEGF splice isoforms as therapeutic targets and prognostic or predictive biomarkers to improve the safety and efficacy of current therapies.
Current Anti-Angiogenic Therapies for CRC: An Overview
In the last decade, different anti-angiogenic strategies have been investigated in preclinical and clinical studies, showing how angiogenesis can be targeted by several approaches. [13] [14] [15] [16] A number of studies have attempted to determine the role of VEGF in angiogenesis, metastasis and proliferation of human CRC cells. In 2000, Ellis and colleagues evaluated the ability of a small molecule inhibitor specific for the tyrosine kinase VEGF receptor Flk-1/KDR (SU5416) or multiple tyrosine kinase receptors (SU6668) to inhibit tumor angiogenesis and metastasis in a model of colon cancer hepatic metastasis. Both SU5416 and SU6668 inhibited metastases, microvessel formation and cell proliferation, while increasing tumor cell and endothelial cell apoptosis. Therefore, these results showed that targeting the VEGF receptor/ligand system is a rational approach to inhibiting tumor growth and prolonging patient survival. 10 However, at present, only three antiangiogenic drugs have been approved by regulatory authorities for the treatment of mCRC: bevacizumab, regorafenib and aflibercept. 17, 18 Bevacizumab has been approved as both first-and second-line treatment of mCRC. 19 Clinical trials suggest that anti-angiogenic treatment with bevacizumab can also be continued beyond first progression although the survival gain is 1.4 months. 19 Newer agents such as regorafenib, ramucirumab and aflibercept have recently been approved in mCRC third and second line therapy, respectively. 20 This evidence suggests that targeting CRC through angiogenesis inhibition following failure of a first anti-angiogenic treatment could be equally successful. However, an important question to consider is regarding the optimal anti-angiogenic strategy to use after a bevacizumab-based first-line therapy. In this scenario, aflibercept or ramucirumab may be optional to target angiogenesis. Addition of aflibercept to FOLFIRI in second-line treatment for mCRC led to a 1.4 months gain in overall survival (OS), which is identical to OS prolongation reached by bevacizumab in second-line treatment in the ML18147 study. 17 When ramucirumab was added to FOL-FIRI there was a 1.6 months improvement in median OS. 21 Whereas, bevacizumab targets angiogenesis through VEGF-A inhibition, aflibercept inhibits VEGF-A, -B and PIGF signaling pathways and ramucirumab is a monoclonal antibody against the VEGF receptor 2 21, 22 ( Fig. 1) . This mechanism of action should allow the blockage of tumor progression at different levels, acting on malignant cells, macrophages and stromal cells that contribute with cooperative mechanisms to tumor neovascularization. 23, 24 Given the different mechanisms of action of aflibercept and ramucirumab in secondline therapy in patients who have progressed on bevacizumab there may be some theoretical benefit in the choice of these agents to overcome resistances, limit the compensatory angiogenic factors and modulate the activity of inflammatory cells within the tumor microenvironment. 17, 25 That said there is currently no randomized data to guide clinicians, there is higher toxicity seen with aflibercept and ramucirumab when compared to bevacizumab, and the cross trial comparison of outcomes are actually similar. Angiogenesis is the process regulating the growth of new vessels from pre-existing vessels, which is critical for the advancement of solid tumors as well as for the metastatic process. 12, 26, 27 The VEGF pathway is an essential regulator of angiogenesis. VEGF family comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D and Placental Growth Factor.
12 VEGF-A is the key regulator of angiogenesis; in fact, several VEGF-A isoforms mediate conflicting effects. Under an hypoxic-state, Hypoxia-Inducible Factor a (HIFa) binds to the hypoxiaresponse element located on the VEGF-A gene, stimulating the transcription of VEGF-A protein. 28 Circulating VEGF-A binds to two VEGF receptors (VEGFR1/FLT1 and VEGFR2/ KDR) and supports endothelial cell survival, proliferation, migration and differentiation. 29 Overexpression of VEGF gene has been associated with advanced stage and poor survival in multiple disease conditions 30 and with several tumors, the majority of disease-associated VEGF-single nucleotide polymorphisms (SNPs) are located within regulatory regions. 31 The VEGF gene is located on chromosome 6p21.3, consists of eight exons that form a family of proteins due to alternative splicing 32 and is highly polymorphic especially in the promoter region and the 3 0 -untranslated region (UTR). 31 Various SNPs in the promoter, 5 0 and 3 0 UTR are present in the VEGF gene as shown in Figure 2 . For instance, 2634G>C SNP which is located in the 5 0 -UTR of VEGF impacts on the protein translation efficiency 32 and 936C>T SNP which is found in the 3 0 -UTR affects the circulating VEGF plasma concentrations and VEGF tumor tissue expression. [33] [34] [35] The organization of the VEGF gene and its transcriptional and post-transcriptional regulation have been widely described by Metzger et al., 31 and a detailed description of VEGF polymorphisms and their association with disease risk has been previously reviewed by Canavese. 30 Focusing on cancer, VEGF SNPs appear to correlate with the risk of developing solid tumors, such as breast cancer, non-small cell lung cancer (NSCLC), CRC and prostate cancer, as previously reviewed by Jain et al. 35 However, the absence of consensus in findings, could be due to dissimilarity in the experimental process and data analysis method. 35 Other possible causes of disagreement could reside in factors concerning the study population, like ethnicity and tumor type, or inadequate sample size when investigating the association with more than one SNP. For instance, the 2634C allele was found to predict higher risk of NSCLC 35 and prostate cancer, 36, 37 as well as reduced risk of CRC. 38, 39 Alternatively, the conflicting outcome of these SNPs could result from the potential parallel presence of unknown functional SNPs within the VEGF gene or unknown SNPs in other angiogenetic factors. Perhaps, rather than individual SNPs, the association with haplotypes could generate a useful predictive approach. 35 Therefore, an in depth understanding of the role and functionality of these polymorphisms in the context of cancer is critical to explain the lack of consensus found in the literature. 40 Moreover, the latest investigations evaluating the role of VEGF polymorphisms examined the cases using appropriate controls to identify and validate biomarkers. It is therefore necessary to take into account also the association of the genotype with drug response, to study and determine genetic markers as well as to monitor the choice of individual treatment.
Can VEGF Splice Isoforms and SNPs be Instrumental as Prognostic Factors for CRC?
With particular focus on colon carcinoma, VEGF has been shown to be an important prognostic marker in cases of advanced CRC, considering that high VEGF expression has been associated with a lower objective response rate 41 and poorer relapse free and OS. 42, 43 Therefore, it is widely thought that VEGF SNPs can be importantly involved in determining the risk, prognosis and survival of CRC patients. Uthoff et al. demonstrated the presence of several splice variants (VEGF121, VEGF145, VEGF165 and VEGF189) and several novel mutations by studying 25 CRC tissues. 44 Single nucleotide changes were found in five samples while in one sample a 2-nucleotide deletion was identified. Moreover, additional mutations have been demonstrated, for example, it was shown that 634C/936C and 2634G/936T correlated with decreased CRC susceptibility. 38 However in most cases the biological and clinical repercussions of these mutations remain unknown. 44 In a larger sample size, studying 445 CRC patients it has been demonstrated that patients with the 2634GC or CC genotypes showed a better survival than those with the 2634GG genotype. 45 In addition, patients showing 936CT or TT genotypes showed worse survival compared to the 936CC genotype. 45 In contrast, VEGF 936C>T, 22578C>A and 634G>C SNPs did not correlate with tumor size, histological grade, regional lymph nodes or tumor stage. 46 In 39 Cetuximab-treated mCRC patients, Zhang et al. reported a significant survival advantage and correlation between cyclin D1 870A>G and the EGF 61A>G SNPs, however no correlation was found for VEGF 936C>T. 47 With regard to predictive biomarkers of response to treatment in mCRC patients, Loupakis et al. analyzed 111 samples from mCRC patients treated with first-line FOLFIRI plus bevacizumab and 107 samples from control mCRC patients treated with FOLFIRI alone. Notably, this study demonstrated a possible role for VEGF 21498 C/T variants in predicting the efficacy of bevacizumab in the first-line treatment of mCRC patients, whereas the control group did not show any significant correlation. 48 Recently, the same group performed 50 A recent meta-analysis evaluated the association between polymorphisms in the VEGF pathway and their value as biomarkers in cancer patients. 51, 52 Notably, these authors confirmed an effect of polymorphisms on both outcome and response to therapy and identified 1405G>C as a marker with significant prognostic value for VEGF targeted therapy. However, it should be taken into account, that this metaanalysis included several variants such as different cancer sites, treatments and ethnic populations. 52, 53 Unfortunately, the study generated contradictory results, limiting its capacity to define the value of this gene as prognostic biomarker. Interestingly, Pare-Brunet et al. found that a total of nine SNPs located in different genes, which have been respectively associated with PFS and correlated with OS in a cohort of mCRC patients treated with first-line oxaliplatin-based chemotherapy. 12 The relevance of these findings lies in the fact that both SNPs maintained their significance regardless of the KRAS mutational status of the cancers. Importantly, this study outlines the clinical relevance of this genetic variant in determining PFS in mCRC patients, and demonstrates that functional germline polymorphisms in the VEGFR-2 and KISS1 genes can be used as predictive biomarkers in mCRC patients regardless of their KRAS mutational status. 12 A SNP in VEGFR1 was found to be significantly associated with increased VEGFR1 expression and poorer PFS and OS in patients treated with bevacizumab. This SNP rs 7993418 is a synonymous SNP that changes the autophosphorylation site and affects signaling mediated by Flt-1. It was shown to be a significant predictor of poor outcome of bevacizumab treatment. 46 The VEGF 22578C>A SNP was not associated with risk, survival, colorectal tumor size and stage. However in Korean women, 22578CA and AA were found to have a threshold protective role. 53 Thus, to evaluate the correlation between VEGF polymorphisms and CRC these data would need to be further confirmed, especially within the context of diverse ethnicity. Further work using new pharmacogenetic technologies would be highly beneficial to characterize the role of VEGF polymorphisms in the development and progression of CRC and as predictive biomarkers.
VEGF-A Isoforms as Prognostic Biomarkers and/or Therapeutic Targets for Colorectal Cancer
Among the VEGF variants, VEGF-A and its receptors are highly expressed in mCRC. Indeed, VEGF-A is regarded as the predominant angiogenic regulator of the spread of CRC to distant organs. VEGF-A is a multi-exon gene, encoding multiple isoforms, with contrasting properties and expression patterns. VEGF-A mRNA splicing generates two families of proteins that differ by their C 0 terminal six amino acids, the pro-angiogenic VEGF-Axxx isoforms and the anti-angiogenic isoforms VEGF-Axxxb, with the designated amino acid number xxx. So far, 12 isoforms of VEGF-A have been identified: VEGF111, VEGF121, VEGF121b, VEGF145, VEGF148, VEGF162, VEGF165, VEGF165b, VEGF183, VEGF189, VEGF189b and VEGF206 43 and their biological properties have been extensively reviewed by Robinson and Stringer. 55 To date, the most common VEGF-A isoform described is the pro-angiogenic VEGF-A165a and the anti-angiogenic VEGFA165b isoform identified in 2002. 24 VEGF-A165b differs from VEGF-A165a by the carboxy-terminal six amino acid substitutions from CDKPRR to SLTRKD. This 6 amino acid difference results in conformational change that prevents VEGF-A165b from binding to neuropilin-1, the co-receptor, as the basic carboxy-terminal amino acids essential for neuropilin-1 is absent, thereby preventing full downstream signaling of VEGF-R2 (Fig. 3) . VEGF-A165b has been shown to exhibit anti-angiogenic properties in several studies. Upregulation of VEGF-A165b is associated with reduced neovasculogenesis in systemic sclerosis, 56, 57 peripheral artery disease 58 and visceral adiposity. 59 An upregulation of the proangiogenic VEGFxxx variants has been widely reported in human tumors. Zhao et al. demonstrated that the alternative splicing in VEGF-A gene provides a prognostic factor and a potential therapeutic target for CRC. 60 All the colon cancers they examined expressed VEGF121. 24 The isoform patterns were classified into three groups: type 1, VEGF-A121; type 2, VEGF-A121 1 VEGF-A165; type 3, VEGF-A121 1 VEGF-A165 1 VEGF-A189. Three of the 61 colon cancers examined showed type 1 expression, 26 showed type 2 expression and 32 showed the type 3 pattern. Notably, patients with liver metastases showed the type-3 isoform expression pattern at a significantly higher frequency (12 of 16, 75%) than those without liver metastasis (20 of 45, 44%) (p 5 0.036). The type-3 isoform pattern was significantly associated with Ml stage (p 5 0.019). Patients with colon cancer and the type-3 isoform pattern showed significantly worse prognosis (p < 0.01, Cox-Mantel) and a significantly higher venous invasion (p 5 0.006). Thus, the aberrant type-3 expression pattern of VEGF189 mRNA isoforms correlates with liver metastasis, M stage, and poor prognosis in colon cancer. 61, 62 The upregulation of VEGF-Axxx isoforms could bring about a loss in the balance among isoforms, which causes a drop in proportion of VEGFxxxb levels. Indeed, VEGFxxxb is downregulated in several cancers, including colorectal carcinoma. 63, 64 It is suggested that the ratio of the pro-vs. antiangiogenic VEGF-A isoforms are potentially the key for controlling and targeting the angiogenesis balance in mCRC. 16, 38, 65 Consistently in three studies, the ratios of VEGF-A121/121b, VEGF-A165/165b were found upregulated in CRC tissues, suggesting a possible role in promoting the development of CRC. 64 In addition, the VEGF-Axxx/VEGFAxxxb ratio affects the sensitivity of tumors to bevacizumab and VEGF-Axxxb can inhibit its effect by competitive binding. 66 Hence, by increasing the amount of VEGF-Axxxb or decreasing the amount of VEGF-Axxx, tumor sensitivity to bevacizumab may be enhanced. 67 It has also been suggested that the differential expression of VEGF-A isoforms, including VEGF-A165/165b in CRC, is a potential prognostic factor and therapeutic target for the treatment of CRC. 68 This view is supported by many studies: Varey et al. showed that the switch from the isoform VEGFAxxxb to VEGF-Axxx is activated in CRC patients. 66 In 30% of CRC patients the ratio between the two isoforms has shifted to VEGF-Axxxb over VEGF-Axxx, as an indication of Figure 3 . Simplified representation of VEGF-A splicing. This simplified figure explains how VEGF-A splicing is organized. VEGF-A mRNA splicing generates two protein families that differ by their C 0 terminal six amino acids, the pro-angiogenic VEGF-Axxx isoforms and the antiangiogenic isoforms VEGF-Axxxb. VEGF-A165b differs from VEGF-A165a by the carboxy-terminal six amino acid substitutions from CDKPRR to SLTRKD. This 6 amino acid difference results in conformational change that prevents VEGF-A165b from binding to neuropilin-1, the coreceptor, as the basic carboxy-terminal amino acids essential for neuropilin-1 is absent, thereby preventing full downstream signaling of VEGF-R2. [Color figure can be viewed at wileyonlinelibrary.com] the fact that a low level of VEGF-A165b expression can be a potential biomarker for poor prognosis in colonic carcinoma. 68 The major limitation regarding the potential use of circulating VEGF-A isoforms is that there are currently no available methods that can differentiate the various proangiogenic VEGF-xxx isoforms, and thus it is difficult to distinguish the ratio of pro-vs. anti-angiogenic VEGF-A circulating isoforms. While circulating VEGF-Axxxb are elevated in systemic sclerosis, 56, 57 peripheral artery disease, 58 obesity 59 and pulmonary hypertension, 69 measured by Enzyme-Linked Immunosorbent Assay (ELISA), the VEGF-Axxxb antibody, while detecting predominantly VEGF-A165b isoform, also detects VEGF-A121b and VEGF-A189b. 64 However, using this ELISA, plasma VEGF-Axxxb levels in patients with CRC were shown to correlate with VEGF-Axxxb levels from colorectal carcinoma specimens, which suggested that circulating VEGF-Axxxb levels can be used as a possible surrogate of tumor relative VEGF-Axxxb levels. 64 Data regarding the potential for use of VEGF-Axxxb circulating levels as biomarkers for CRC metastases are required to validate its uses.
VEGF-A Isoforms and Resistance to Anti-VEGF Therapy
Bevacizumab, which was approved for clinical use in CRC patients in 2004, 70 is a humanized monoclonal antibody that inhibits both the VEGF-Axxx and VEGF-Axxxb isoforms by blocking their common kinase-domain-receptor binding site. 66 Bates et al. demonstrated that low VEGF-A165b: VEGF total ratio could represent a predictive marker for bevacizumab efficacy in mCRC, where individuals with high ratios possibly will not benefit. 65 This was confirmed by Bunni et al. who also suggested that plasma VEGF-Axxxb levels could be an effective biomarker of response to bevacizumab. Therefore, a prospective trial would be warranted to explore the use of plasma VEGF-Axxxb levels to stratify patients for CRC treatment with bevacizumab. 64 Interestingly, Tayama et al. characterized the implications of VEGF-A in stromal cells (s-VEGF-A) and CRC and the expression of VEGF-A splice variants. 71 Based on their observation that s-VEGF-A, including VEGF165b inhibits neoangiogenesis, these authors proposed that CD681 stromal cells secrete VEGF165b and thus inhibit the angiogenesis induced by VEGF165 secretion by tumor cells. 71 Indeed, overexpression of VEGF165b has been reported to delay the growth of several tumors, including CRC. 61 Notably, VEGF-A165b is neutralized by a greater number of anti-VEGF-A antibodies, including bevacizumab. 66 Other factors interacting with VEGF-A also influence the ratio of VEGF isoforms. Recently, alternative splicing of Tcell Intracellular Antigen-1 (TIA-1), a translational regulator of VEGF, resulting in a truncated short (S) TIA-1 isoform was reported to be expressed at a higher level in CRC compared to normal colon tissue and was associated with significantly higher microvessel density. Whereas full length TIA-1 selectively bound VEGF-A165 mRNA and increased translation of VEGF-A165b, sTIA-1 prevented this binding and reduced translation of the VEGF165b (the anti-angiogenic) isoform. This alternative splice variant would lead to increased angiogenesis and resistance to anti-VEGF therapy. 72 Despite the effectiveness of bevacizumab when it is combined with cytotoxic agents, it has been reported to have a low response rate, high rate of resistance and adverse events that have been discussed elsewhere. 73, 74 Most tumors harbor hypoxic areas that are refractory to chemotherapy and radiotherapy and lead to selection of metabolically altered tumor cell populations that are tolerant to low oxygen tension. These populations undergo further selection to a more invasive and metastatic phenotype that is resistant to antiangiogenic agents. Furthermore, VEGF blockade contributes to hypoxia and stimulates production of alternative angiogenic factors which exacerbates the problem of resistance (reviewed in Ribatti 2016). 75 In addition, non-specific targeting, due to the lack of specificity of the antibody to either pro-or the anti-angiogenic VEGF-A isoforms, could contribute to the drawbacks associated with bevacizumab. To address this challenge, strategies specifically blocking the VEGF-Axxx subfamily have been explored, and pegaptanib was developed as a short modified RNA aptamer that specifically binds to VEGF-Axxx but not VEGF-Axxxb. 61, 76 Alternative therapeutic strategies could utilize VEGFxxx specific antibodies, which exclusively inhibit the pro-angiogenic isoforms or develop molecules able to favor the anti-angiogenic VEGFxxxb isoforms formed by distal splice-site (DSS) selection, and thus increase the endogenous expression of VEGFxxxb. 61, 77 Indeed, Liu et al. isolated
and characterized a human anti-VEGF165 monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci. 18 In addition, it has been shown that knocking down SRPK1 in a colorectal tumor cell line sensitive to the anti-angiogenic actions of VEGF165b decreases tumor growth in vivo. 15 Another possible target for CRC is a trans-element, SRp55, which is known to increase VEGF-Axxxb expression, leading to anti-angiogenic effects. 60 Finally, in vivo treatment with recombinant human VEGF165b has shown a growth-inhibitory effect in CRC 60, 68 and several other types of cancer. 63 Therefore, taken together these studies highlight the potential role of VEGF165b as an anti-cancer agent. However, a proper selection of patients that can benefit from this treatment is essential, as recombinant human VEGF165b-based therapies, for example, are likely to be effective only in tumors with high VEGF expression and low VEGFA165b: VEGF total ratio, since tumors with low VEGF levels must rely on other pro-angiogenic factors. 66, 67, 76 Available VEGF-based therapies are summarized in Table 1 as well as the targeted therapies for mCRC are reviewed by Kirstein et al. 20 
Conclusions
In summary, targeting VEGF pathways is a favorable therapeutic strategy for mCRC. The clinical development of antiangiogenic therapy is now at an advanced stage in a variety of cancers including mCRC, however in contradiction to anti-EGFR treatments for which patients can be selected based on available predictive biomarkers and companion diagnostic assays, predictive biomarkers of response to treatment with anti-VEGF agents have not been validated. Therefore, the question whether treatment with the humanized monoclonal antibody bevacizumab, which does not neutralize a specific VEGF-A isoform can generate significant anticancer benefit remains open. 74 Newer agents with differing targets (aflibercept and ramucirumab with chemotherapy and regorafenib as a single agent) have shown similar survival gains in mCRC. 11, 20 The management of mCRC in progressive disease stages using various therapeutic agents, including anti-angiogenic compounds, will require predictive biomarkers for informed selection of treatment combinations.
Recently it has been demonstrated that VEGF-Axxxb isoforms are key regulators of angiogenesis in health and disease. Exogenously (intravenously) administered recombinant VEGF-A165b appears to accumulate in tumors (presumably because it targets VEGFR2-bearing tumor microvessels) and therefore has increased tumor bioavailability. Thus, administration of recombinant VEGF-Axxxb isoforms could be a novel therapeutic approach in the short term. However, the most effective but also the most challenging approach in the long term may be to allow cancer VEGF-A transcription to proceed unhindered but to control splicing such that the spliceosome opts for exon 8 distal splice site selection in place of exon 8 proximal splice site selection. This would effectively cause the cancer to switch off its own nutrient supply. Indeed, given that the VEGF-A promoter contains a hypoxia response element, the more hypoxic the tumor became, the more effective this switch might be. In conclusion, since there is a switch from anti to pro-angiogenic isoforms of VEGF in colonic tumors it is believed that regulation of the ratio of pro to anti-angiogenic isoforms of VEGF by altering splicing is potentially therapeutic for tumors and other angiogenesisassociated diseases and will be a focus of future research.
